Health Canada Grants Selected Physicians Access to Psilocybin Mushrooms as Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Dives into Functional Mushroom Market

  • Health Canada recently granted psilocybin testing access to selected physicians
  • Psilocybin mushrooms shown to help patients suffering from addiction, mental health issues
  • Pure Extracts’ ’Pure Mushrooms’ and ‘Pure Pulls’ branded products expected to be available by end of Q1 2021

In a recent virtual townhall, Canadian Health Minister Patty Hajdu disclosed that the Canadian government has recently granted access to psilocybin or “psychedelic” mushrooms to several physicians for use in patients with addiction and/or mental health issues (https://ibn.fm/j9ZAO). In line with anticipated legislation expected to loosen restrictions on psilocybin mushrooms, Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a Canadian plant-based extraction company with a new vertical in functional mushrooms, is currently positioning itself to be the dominant extraction company and leader in the rapid development and commercialization of functional and medicinal products.

Hajdu’s comments were part of a discussion on several health-related topics at a recent Vancouver B.C. virtual townhall with the Honourable Hedy Fry, a Canadian parliament representative. In response to Fry’s questions concerning the use of psilocybin mushrooms, Hajdu disclosed that the government was taking the discussion into the mainstream by granting some physicians access to the mushrooms for testing purposes.

“Health Canada approved some physicians access to psilocybin mushrooms to test,” said Hajdu. “We are still testing these mushrooms and their effects, and we are taking these discussions out of the shadows and into more of a mainstream conversation.”

In anticipation of relaxed laws around the use of psilocybin mushrooms, Pure Extracts is building-out its existing cannabis-processing infrastructure to accommodate mushroom extraction processes as part of its overall market penetration strategy. The Company operates out of its state-of-the-art facility in British Columbia, Canada that is built to European Union GMP standards for the purpose of obtaining EU-GMP certification in order to export to European countries, where both cannabis and functional mushroom products are legal for sale and consumption.

Rather than operate in the saturated cultivation market, Pure Extracts instead purchases in bulk from Licensed Producers for further extraction processing via a Health Canada Standard Processing License granted to Pure Extracts Manufacturing Corp., its wholly-owned subsidiary. Along with both cannabis and hemp biomass processing and white labeling for Licensed Producers, the Company has also developed private label products that include the mushroom-based ‘Pure Mushrooms’ line and the ‘Pure Pulls’ line of cannabis products.

“We intend to launch these products in Q1 from an online portal that we are developing,” said Pure Extracts’ CEO, Ben Nikolaevsky (https://ibn.fm/VIK6n). “Functional mushrooms have been identified as the new ‘wonder’ product in the wellness space and have been rapidly growing in popularity, so this is a very exciting move for us.”

Pure Extracts was incorporated under the British Columbia Business Corporations Act and is headquartered just north of Whistler, British Columbia. Along with being granted its Standard Processing License by Health Canada on September 25, 2020, the Company also started trading on the Canadian Securities Exchange on November 5, 2020 under the symbol “PULL”.

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Archives

Select A Month

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050